A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD8683 After Single Ascending Doses Administered Via Turbuhaler in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs AZD 8683 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 01 May 2012 Actual patient number added 38 according to ClinicalTrials.gov.
- 01 May 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.